Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Richard Charles Sewell has worked on the following 6 EPO patent applications which have been published in the last five years:

EP13799318

MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR-GAMMA) FOR USE IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES

IPC classification:
A61K 31/495, A61K 31/496, A61K 31/497, A61K 31/501, A61K 31/506, C07D 241/04, C07D 401/12, C07D 401/14, C07D 403/12, C07D 407/12, C07D 413/12, C07D 413/14, C07D 417/12, C07D 417/14, C07D 471/04
Applicant:
Glaxo Group Limited
Agent:
Richard Charles Sewell, GlaxoSmithKline
Status:
The patent has been granted
EP14855946

NOVEL COMPOUNDS

IPC classification:
C07D 213/75, C07D 257/04, C07D 261/08
Applicant:
GlaxoSmithKline LLC
Agent:
Richard Charles Sewell, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15726090

1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS

IPC classification:
A61K 31/17, A61P 11/00, A61P 29/00, C07C 211/56, C07C 275/30, C07D 207/10, C07D 211/54, C07D 213/34, C07D 233/64, C07D 239/26, C07D 295/135, C07D 305/06, C07D 307/18, C07D 309/08, C07D 471/04, C07D 487/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Richard Charles Sewell, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15799481

NOVEL COMPOUNDS

IPC classification:
A61K 31/495, A61P 37/02, C07D 403/00
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Richard Charles Sewell, GlaxoSmithKline
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature